Xi'an Faithful BioTech Co., Ltd. is selling Semaglutide Raw Powder. Please feel free to contact us if you have any purchase needs.
Semaglutide is in a class of medications called incretin mimetics. It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
I. Introduction: The Development of GLP-1 Products and Semaglutide's Industry Positioning
1.1 The Global Burden of Metabolic Diseases
With the acceleration of global urbanization and lifestyle changes, metabolic diseases such as type 2 diabetes and obesity have become major public health challenges. According to data from the International Diabetes Federation (IDF), there were 537 million people with type 2 diabetes worldwide in 2024, with Chinese patients accounting for over 25%, and approximately 60% of diabetes patients also having overweight or obesity. Obesity is not only an independent risk factor for type 2 diabetes, but also significantly increases the risk of complications such as cardiovascular disease and chronic kidney disease, placing a heavy burden on healthcare systems.
1.2 The Development History and Technological Evolution of GLP-1 Products
Glucagon-like peptide-1 (GLP-1) is an incretin secreted by intestinal L cells. It has the characteristic of regulating insulin and glucagon secretion in a glucose concentration-dependent manner, providing an ideal target for the treatment of metabolic diseases. In 1998, the first GLP-1 product, Exendin-4 (short-acting), was approved for marketing, initiating a therapeutic revolution in this field. Subsequently, Liraglutide, through fatty acid side-chain modification, achieved once-daily administration, becoming the first GLP-1 product to combine blood sugar lowering and weight loss effects, but the convenience of long-term use remained unresolved.
Semaglutide was first approved in the EU in 2017. Through peptide chain structure optimization and dual modification technology, it extended its half-life to 7 days, enabling weekly administration and fundamentally changing the clinical application model of GLP-1 products. As of 2025, Semaglutide has been approved in over 100 countries worldwide, covering multiple indications including type 2 diabetes, obesity/overweight management, and cardiovascular risk reduction. In 2024, global sales reached nearly $30 billion, accounting for 50% of the GLP-1 product market share, making it a benchmark product in the field.
II. Breakthrough in Semaglutide Research and Mechanism of Action
2.1 Core Technological Innovation in Molecular Structure Modification
The success of Semaglutide stems from Novo Nordisk's accumulated expertise in peptide product modification. Its molecular structure optimization is primarily reflected in two key dimensions: First, amino acid sequence modification, by replacing the 8th alanine residue of natural GLP-1 with α-aminoisobutyric acid (Aib), effectively resisting degradation by dipeptidyl peptidase-4 (DPP-4) and extending its survival time in vivo; second, fatty acid side chain modification, by attaching a C18 fatty acid diacid chain to the 26th lysine residue of the peptide chain. This side chain can form a non-covalent bond with albumin, further extending its half-life and reducing renal clearance, thus improving its bioavailability.
2.2 Mechanism of Action and Scientific Basis of Multi-Target Regulation
Semaglutide specifically binds to GLP-1 receptors, activating downstream signaling pathways to achieve multi-dimensional regulation of the metabolic system. Its mechanism of action is glucose concentration-dependent, effectively reducing the risk of hypoglycemia. Specifically, it includes the following core mechanisms:
2.2.1 Precise Mechanism of Glucose Regulation
In a hyperglycemic state, semaglutide activates GLP-1 receptors on the surface of pancreatic β-cells, promoting insulin granule exocytosis and increasing insulin secretion; simultaneously, it inhibits glucagon secretion from pancreatic α-cells, reducing hepatic glycogenolysis and gluconeogenesis. Furthermore, it slows gastric emptying and reduces postprandial glucose absorption, forming a triple hypoglycemic effect of "promoting secretion, inhibiting hyperglycemia, and slowing absorption."
2.2.2 Neuro-metabolic Regulatory Pathway for Weight Management
Semaglutide crosses the blood-brain barrier into the central nervous system, acting on the appetite regulation center in the hypothalamus, inhibiting the activity of AgRP-related neurons and activating pro-opioid-metabolizing neurons, thereby suppressing appetite and enhancing satiety. Simultaneously, it can act on adipose tissue, reducing the activity of lipases, promoting the browning of white adipose tissue, and increasing energy expenditure.
2.2.3 Multifunctional Mechanism of Cardiovascular and Renal Protection Semaglutide's target organ protective effects extend beyond metabolic regulation itself: In the cardiovascular system, it can improve vascular endothelial function, lower blood pressure (average decrease of 3-5 mmHg in systolic blood pressure), regulate blood lipids (reducing LDL-C by approximately 10%), and reduce the formation of atherosclerotic plaques; in the renal system, it slows the progression of chronic kidney disease by reducing glomerular pressure, reducing urinary protein excretion (a 52% reduction in urinary protein levels after 24 weeks of treatment), and inhibiting renal inflammatory responses.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
III. Clinical Evidence and Indication Expansion for Semaglutide
3.1 Clinical Research Support for Core Indications
3.1.1 Stratified Application in Type 2 Diabetes Treatment
Semaglutide is applicable in multiple stages of type 2 diabetes treatment: For treatment-naïve patients, a starting dose of 0.5 mg can rapidly control blood glucose, achieving HbA1c target rates (<7%) of 78%; combined use with semaglutide can further reduce HbA1c by 1.2%, with a hypoglycemic incidence of only 2.3%, significantly lower than insulin combination therapy (15.6%).
3.1.2 Precise Targeting of Obesity/Overweight Management
The FDA-approved obesity indication clearly defines the suitable population for semaglutide: BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with metabolic complications such as hyperglycemia and hypertension. The STEP 4 trial showed that after weight loss to the target level, maintenance therapy with a 2.4 mg dose effectively delayed weight rebound, with a 1-year maintenance rate of 72%, compared to a 67% weight rebound rate in the placebo group. Notably, this product is also effective in non-diabetic obese patients, resulting in a 10% weight loss after 24 weeks of treatment, while simultaneously improving insulin resistance and blood pressure levels.
3.1.3 Clinical Evidence in Specific Populations
For type 2 diabetic patients with cardiovascular disease, a dose of 1.0 mg of semaglutide significantly reduces the risk of adverse events such as myocardial infarction and stroke, regardless of baseline HbA1c levels. For patients with chronic kidney disease, even when the estimated glomerular filtration rate (eGFR) drops to 30-45 ml/min/1.73 m², no dose adjustment is required, and the rate of renal function decline can be slowed.
3.2 Development Progress of Potential Indications
The clinical value of semaglutide is constantly expanding, with several new indications currently in clinical trials: In the field of non-alcoholic steatohepatitis (NASH), animal experiments have shown that it can reduce hepatic steatosis and inflammatory response, and phase 2 clinical trials have confirmed its effect in reducing liver fibrosis scores; in the field of Alzheimer's disease, the expression of GLP-1 receptors in the cognitive regions of the brain provides a theoretical basis for product application, and preliminary studies show that it can improve memory function in patients with mild cognitive impairment; in addition, its therapeutic potential in diseases such as alcohol dependence and polycystic ovary syndrome (PCOS) is also being explored.
IV. Global Market Landscape of Semaglutide
4.1 Global Market Size and Growth Drivers
GLP-1 products have become one of the fastest-growing sectors in the global pharmaceutical market, with global sales exceeding US$50 billion in 2024. Semaglutide dominates this sector with sales of nearly US$30 billion, a 45% increase compared to 2023. Growth is primarily driven by three factors: first, the explosive growth in market demand for obesity-related indications, with global sales of weight loss products reaching $14 billion in 2024, of which Semaglutide accounted for over 60%; second, the expansion of the patient population due to cardiovascular and renal protection indications.
Regionally, the United States is Semaglutide's largest market, accounting for 62% of sales in 2024, mainly due to its large obese population and broad commercial insurance coverage; the European market accounts for 23%, with broad accessibility for diabetes indications achieved through health insurance negotiations; the Asia-Pacific market saw the fastest growth, with a growth rate of 58% in 2024, with China being the core growth engine.
V. Industry Challenges Facing Semaglutide
5.1 Patent Barriers and the Impact of Generic Drugs Novo Nordisk has built a multi-layered patent protection system for Semaglutide, including compound patents, preparation method patents, and dosage form patents, but the expiration dates of its core compound patents in major markets are concentrated between 2026 and 2032. In the United States, companies such as Teva and Mylan have already submitted applications for generic versions, and the first generic product is expected to be launched in 2027. Novo Nordisk's response strategy includes advancing its patent portfolio for high-dose formulations (7.2 mg) and developing follow-up products such as GLP-1/GIP dual agonists.
VI. Future Trends: Indication Expansion and Industry Development Direction
6.1 Diversification of Indications
Semaglutide's indication expansion is progressing along the path of "metabolic diseases - target organ protection - neurological diseases." In the metabolic field, Phase 3 clinical trials for NASH and PCOS have entered a critical phase, with approval expected in 2026-2027; in the target organ protection field, applications for indications in heart failure and chronic kidney disease have been submitted to the FDA, potentially making it the first GLP-1 product for non-diabetic nephropathy patients; in the neurological field, Phase 2 trials for Alzheimer's disease and Parkinson's disease have shown neuroprotective potential, opening up new therapeutic areas for this type of product.
6.2 Restructuring of the Industry Ecosystem
With the launch of generic products and intensified market competition, the GLP-1 product industry will shift from a "monopoly of original drugs" to a "tiered competition" pattern: original drugs will focus on the high-end market and new indications, while generic drugs will occupy the basic treatment market.
Conclusion
Semaglutide, with its groundbreaking long-acting technology and multiple clinical benefits, has reshaped the treatment philosophy for metabolic diseases, becoming a benchmark product in the GLP-1 inhibitor industry. Its molecular structure modification technology has provided a paradigm for peptide product development, and clinical evidence has confirmed its remarkable efficacy in areas such as blood sugar control, weight loss, and target organ protection. The rapid growth of its global market size demonstrates its immense industry value. However, facing multiple challenges including patent expiration in 2026, competition from generic products, and safety controversies, Semaglutide's industry position will depend on subsequent indication expansion, formulation innovation, and market standardization.
From an industry development perspective, the success of Semaglutide has not only driven technological iteration in GLP-1 inhibitors but also sparked in-depth exploration of multi-target therapies for metabolic diseases. In the future, with advancements in precision medicine technology and formulation processes, as well as the continuous improvement of industry standards, Semaglutide will play a role in a wider range of disease areas, while simultaneously driving the entire metabolic disease treatment industry towards a safer, more effective, and more accessible direction. For businesses, the focus should be on technological innovation and differentiated competition; for clinical institutions, the principles of evidence-based medicine should be upheld and usage should be standardized; for policymakers, the balance between innovation protection and the needs of the people should be maintained, and a healthy and orderly market ecosystem should be built.
As a provider of premium Semaglutide CAS 910463-68-2, Xi'an Faithful BioTech Co., Ltd. leverages state-of-the-art production technology and rigorous quality assurance to meet international pharmaceutical requirements. Our dedication to superior quality, cost-effective pricing, and tailored technical support has made us the preferred collaborator for healthcare professionals and researchers worldwide. To obtain detailed specifications and application guidance for our Semaglutide Powder, contact our technical team at sales4@faithfulbio.com and explore how our offerings can enhance your product formulations.